Dehydroeffusol effectively inhibits human gastric cancer cell-mediated vasculogenic mimicry with low toxicity

Liu, Wenming; Meng, Mei; Zhang, Bin; Du, Longsheng; Pan, Yanyan; Yang, Ping; Gu, Zhifeng; Zhou, Quansheng; Cao, Zhifei

doi:10.1016/j.taap.2015.05.003

Cited by 37 publications

(27 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We believed that one possible reason might be that the drugs used in traditional anti-angiogenic therapy tend to be anti-VEGF agents which play a role mainly by reducing endothelial cell proliferation or inducing endothelial cell apoptosis, while these drugs have little effect on vasculogenic mimicry (VM) formed by tumor cells. Many chemotherapeutic agents, including paclitaxel or plus artemether, epirubicin plus celecoxib, vincristine plus dasatinib, ginsenoside Rg3, endostatin, all-trans retinoic acid and dehydroeffusol, have been used for anti-VM [13, 22–27]. …”

Section: Discussionmentioning

confidence: 99%

Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy

et al. 2016

View full text Add to dashboard Cite

Like the anti-angiogenic strategy, anti-vascular mimicry is considered as a novel targeting strategy for glioma. In the present study, we used NGR as a targeting ligand and prepared NGR-modified liposomes containing combretastatin A4 (NGR-SSL-CA4) in order to evaluate their potential targeting of glioma tumor cells and vasculogenic mimicry (VM) formed by glioma cells as well as their anti-VM activity in mice with glioma tumor cells. NGR-SSL-CA4 was prepared by a thin-film hydration method. The in vitro targeting of U87-MG (human glioma tumor cells) by NGR-modified liposomes was evaluated. The in vivo targeting activity of NGR-modified liposomes was tested in U87-MG orthotopic tumor-bearing nude mice. The anti-VM activity of NGR-SSL-CA4 was also investigated in vitro and in vivo. The targeting activity of the NGR-modified liposomes was demonstrated by in vitro flow cytometry and in vivo biodistribution. The in vitro anti-VM activity of NGR-SSL-CA4 was indicated in a series of cell migration and VM channel experiments. NGR-SSL-CA4 produced very marked anti-tumor and anti-VM activity in U87-MG orthotopic tumor-bearing mice in vivo. Overall, the NGR-SSL-CA4 has great potential in the multi-targeting therapy of glioma involving U87-MG cells, and the VM formed by U87-MG cells as well as endothelial cells producing anti-U87-MG cells, and anti-VM formed by U87-MG cells as well as anti-endothelial cell activity.

show abstract

Section: Discussionmentioning

confidence: 99%

Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Metastasis of malignant tumor is the main reason for the failure of tumor treatment. It was reported that tumor metastasis was mainly caused by the adhesiveness of tumor cells to extracellular matrix [8], the migration ability of tumor cells [9], the formation of vasculogenic mimicry channels (VM) [10] and the expression of related proteins, such as MMP-2, MMP-9, FAK and PI3K [11].…”

Section: Introductionmentioning

confidence: 99%

Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma

Xiao

Cheng

Xie

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Glioma is the most common primary malignant brain tumor with a poor prognosis. The application of chemotherapeutic drugs is limited due to the existence of blood-brain barrier and serious side effects. Liposomes have been proven to be a stable and useful drug delivery system for tumors. In this paper, WGA (wheat germ agglutinin) modified vinorelbine cationic liposomes had been successfully constructed for treating glioma. In the liposomes, WGA was modified on the liposomal surface for crossing the blood-brain barrier and increasing the targeting effects, 3-(N-(N 0 , N 0-dimethylaminoethane) carbamoyl) cholesterol (DC-Chol) was used as cationic material and vinorelbine was encapsulated in the aqueous core of liposomes to inhibit tumor metastasis and kill tumor cells. Studies were performed on C6 cells in vitro and were verified in brain glioma-bearing mice in vivo. Results in vitro demonstrated that the targeting liposomes could induce C6 cells apoptosis, promote drugs across the blood-brain barrier, inhibit the metastasis of tumor cells and increase targeting effects to tumor cells. Meanwhile, action mechanism studies showed that the targeting liposomes could down-regulate PI3K, MMP-2, MMP-9 and FAK to inhibit tumor metastasis. Results in vivo exhibited that the targeting liposomes displayed an obvious antitumor efficacy by accumulating selectively in tumor site and exhibited low toxicity to blood system and major organs. Hence, WGA modified vinorelbine cationic liposomes might provide a safe and efficient therapy strategy for glioma.

show abstract

“…The wound healing assay was used to evaluate cell migration in this study as we previously described (Bao et al 2012;Liu et al 2015c). Briefly, ovarian cancer cells transfected with miR-27b mimics or scrambled miR-27b were first cultured in six-well plates to confluence, and then scraped with the fine end of a pipette tip and washed three times with PBS to remove detached cells (time 0).…”

Section: Cell Migration Assaymentioning

confidence: 99%

“…The tumor cell invasion assay was performed using Transwell chambers as reported previously (Bao et al 2012;Liu et al 2015c). Briefly, cells transfected with miR-27b mimics or scrambled miR-27b were suspended with serum-free medium.…”

Section: Cell Invasion Assaymentioning

confidence: 99%

“…In normal tissues and cells, VE-cadherin is restrictively expressed in vascular endothelial cells, not in various other normal tissues and cells; however, it is aberrantly overexpressed in various malignant tumors (Hendrix et al 2001(Hendrix et al , 2016Seftor et al 2012;Cao et al 2013b,c;Mao et al 2013). Convincingly, either blocking the cell membrane surface VE-cadherin with a specific antibody against the protein (May et al 2005), or down-regulation of VE-cadherin gene expression by small molecules, results in diminishing the neovascularization of malignant tumors including ovarian cancer (Bao et al 2012;Cao et al 2013c;Liu et al 2015c;Tang et al 2016). Hence, tumor cell VE-cadherin has been selected as a target for novel antitumor vasculogenic and anticancerous drug discovery.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression

Liu

Zhang

et al. 2017

RNA

Self Cite

View full text Add to dashboard Cite

Aggressive cancer cells gain robust tumor vascular mimicry (VM) capability that promotes tumor growth and metastasis. is aberrantly overexpressed in vasculogenic cancer cells and regarded as a master gene of tumor VM. Although microRNAs (miRNAs) play an important role in modulating tumor angiogenesis and cancer metastasis, the miRNA that targets expression in cancer cells to inhibit tumor cell-mediated VM is enigmatic. In this study, we found that miR-27b levels are negatively co-related to expression in ovarian cancer cells and tumor cell-mediated VM, and demonstrated that miR-27b could bind to the 3'-untranslated region (3'UTR) of mRNA. Overexpression of miR-27b in aggressive ovarian cancer cell lines Hey1B and ES2 significantly diminished intracellular expression; convincingly, the inhibitory effect of miR-27b could be reversed by miR-27b specific inhibitor. Intriguingly, miR-27b not only effectively suppressed ovarian cancer cell migration and invasion, but also markedly inhibited formation of ovarian cancer cell-mediated capillary-like structures in vitro and suppressed generation of functional tumor blood vessels in mice. Together, our study suggests that miR-27b functions as a new inhibitor of ovarian cancer cell-mediated VM through suppression of expression, providing a new potential drug candidate for antitumor VM and anti-ovarian cancer therapy.

show abstract

Dehydroeffusol effectively inhibits human gastric cancer cell-mediated vasculogenic mimicry with low toxicity

Cited by 37 publications

References 38 publications

Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy

Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy

Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma

MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression

Contact Info

Product

Resources

About